COMPANY

Actio Biosciences

Keywords: small molecule rare disease rare diseases KCNT1-Related Epilepsy ABS-1230

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Raises and deals from press releases

Deal Jazz Pharmaceuticals deal · $820M upfront · announced Aug 10, 2026 Company release ↗
Source quote
- Aug 10, 2026 · Company release ↗
  “Jazz to acquire privately-held Actio Biosciences for $820 million upfront and up to $500 million in contingent consideration”

From the company’s own releases; this list is partial. All raises and deals

May 18, 2026 Trial start Phase 2: A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy source ↗
Aug 28, 2025 Trial start Phase 1: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years source ↗
Jun 18, 2025 Raise Private equity round — Series B: $66M (total, as published), announced Jun 18, 2025. Source: company's own press page. source ↗

2026-12 (ESTIMATED) · Phase 1 · A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years · NCT07156201
2027-01 (ESTIMATED) · Phase 2 · A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy · NCT07600736

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $66.0M. Last 2 years.

Jun 18, 2025 Private equity round — Series B: $66M (total, as published), announced Jun 18, 2025. Source: company's own press page. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07156201	A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years	Phase 1	Recruiting	Aug 28, 2025	2026-12 (estimated)
NCT07600736	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy	Phase 2	Recruiting	May 18, 2026	2027-01 (estimated)